Chronic fatigue syndrome
Rosamund Vallings 1
+ Author Affiliations
- Author Affiliations
Howick Health and Medical Centre, 108 Ridge Road, Howick, Auckland, New Zealand. Email: Vallings@xtra.co.nz
Journal of Primary Health Care 11(4) 295-299 https://doi.org/10.1071/HCv11n4_ED2
Published: 18 December 2019
Journal Compilation © Royal New Zealand College of General Practitioners 2019 This is an open access article licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License
References
[1] McEvedy CP, Beard AW. Concept of Benign Myalgic Encephalomyelitis. BMJ 1970; 1 11–5.| Concept of Benign Myalgic Encephalomyelitis.Crossref | GoogleScholarGoogle Scholar |
[2] Committee on the diagnostic criteria for ME/CFS Beyond ME/CFS – redefining an illness. Washington, DC: Institute of Medicine, National Academic Press; 2015.
[3] Jason LA, Richman JA, Rademaker AW, et al. A community based study of chronic fatigue syndrome. Arch Intern Med 1999; 159 2129–37.
| A community based study of chronic fatigue syndrome.Crossref | GoogleScholarGoogle Scholar |
[4] Kerr JR. Gene profiling of patients with chronic fatigue syndrome/myalgic encephalomyelitis. Curr Rheumatol Rep 2008; 10 482–91.
| Gene profiling of patients with chronic fatigue syndrome/myalgic encephalomyelitis.Crossref | GoogleScholarGoogle Scholar |
[5] Buchwald D, Herrell R, Ashton S, et al. A twin study of chronic fatigue. Psychosom Med 2001; 63 936–43.
| A twin study of chronic fatigue.Crossref | GoogleScholarGoogle Scholar |
[6] Evans MA, Jason LA. Onset patterns of chronic fatigue syndrome and myalgic encephalomyelitis. Res Chron Dis. 2018; 2 1–30.
[7] Glassford JAG. The neuroinflammatory etiopathology of myalgic encephalomyelitis/chronic fatigue syndrome. Front Physiol 2017; 8 88
| The neuroinflammatory etiopathology of myalgic encephalomyelitis/chronic fatigue syndrome.Crossref | GoogleScholarGoogle Scholar |
[8] Hardcastle SL, Brenu EW, Johnston S, et al. Characterisation of cell functions and receptors in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis. BMC Immunol 2015; 16 35
| Characterisation of cell functions and receptors in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis.Crossref | GoogleScholarGoogle Scholar |
[9] Rowe PC, Underhill RA, Friedman KJ, et al. Myalgic encephalomyelitis/chronic fatigue syndrome diagnosis and management in young people: A primer. Front Pediatr 2017; 5 121
| Myalgic encephalomyelitis/chronic fatigue syndrome diagnosis and management in young people: A primer.Crossref | GoogleScholarGoogle Scholar |
[10] Lampner C. Addressing depression in myalgic encephalomyelitis/chronic fatigue syndrome. 2018. [cited 2018 May 14] Psychiatry Advisor.com. Available from: https://www.psychiatryadvisor.com/home/depression-advisor/addressing-depression-in-myalgic-encephalomyelitis-chronic-fatigue-syndrome/
[11] Fukuda K, Straus SE, Hick I, et al. The chronic fatigue syndrome: a comprehensive approach to its definition and study. Ann Intern Med 1994; 121 953–9.
| The chronic fatigue syndrome: a comprehensive approach to its definition and study.Crossref | GoogleScholarGoogle Scholar |
[12] Chronic fatigue syndrome/myalgic encephalomyelitis – primer for clinical practitioners (2014). http://iacfsme.org/portals/0/pdf/Primer_Post_2014_conference.pdf – includes information about Canadian and International diagnostic criteria.
[13] Light AR, Bateman D, Hughen RW, et al. Gene expression alteration at baseline and following moderate exercise in patients with CFS and fibromyalgia syndrome. J Intern Med 2012; 271 64–81.
| Gene expression alteration at baseline and following moderate exercise in patients with CFS and fibromyalgia syndrome.Crossref | GoogleScholarGoogle Scholar |
[14] Tomas C, Brown A, Strassheim V, et al. Cellular bioenergetics is impaired in patients with chronic fatigue syndrome. PLoS One 2018; 13 e0192817
| Cellular bioenergetics is impaired in patients with chronic fatigue syndrome.Crossref | GoogleScholarGoogle Scholar |
[15] Black R. New insights into exercise intolerance and medication. Bateman Horne Centre News, ME/CFS, Research News. July 27, 2018.
[16] Burnet RB, Chatterton BE. Gastric emptying is slow in chronic fatigue syndrome. BMC Gastroenterol 2004; 4 32
| Gastric emptying is slow in chronic fatigue syndrome.Crossref | GoogleScholarGoogle Scholar |
[17] Rowe PC, Marden CL, Jasion SE, et al. Cow’s milk protein intolerance in adolescents and young adults with chronic fatigue syndrome. Acta Paediatr 2016; 105 e412
| Cow’s milk protein intolerance in adolescents and young adults with chronic fatigue syndrome.Crossref | GoogleScholarGoogle Scholar |
[18] Joustra ML, Minovic I, Janssens KAM, et al. Vitamin and mineral status in chronic fatigue syndrome and fibromyalgia syndrome: A systematic review and meta-analysis. PLoS One 2017; 12 e0176631
| Vitamin and mineral status in chronic fatigue syndrome and fibromyalgia syndrome: A systematic review and meta-analysis.Crossref | GoogleScholarGoogle Scholar |
[19] Morris G, Anderson G, Berk M, Maes M. Coenzyme Q10 depletion in medical and neuropsychiatric disorders: potential repercussions and therapeutic implications. Mol Neurobiol 2013; 48 883–903.
| Coenzyme Q10 depletion in medical and neuropsychiatric disorders: potential repercussions and therapeutic implications.Crossref | GoogleScholarGoogle Scholar |
[20] Rolles B, Maywold M, Rink L. Influence of zinc deficiency and supplementation on NK cell cytotoxicity. J Funct Foods 2018; 48 322–8.
| Influence of zinc deficiency and supplementation on NK cell cytotoxicity.Crossref | GoogleScholarGoogle Scholar |
[21] Regland B, Forsmark S, Halaouate L, et al. Response to vitamin B12 and folic acid in myalgic encephalomyelitis and fibromyalgia. PLoS One 2015; 10 e0124648
| Response to vitamin B12 and folic acid in myalgic encephalomyelitis and fibromyalgia.Crossref | GoogleScholarGoogle Scholar |
[22] Streeten DHPBel DSl.
[23] Castro-Marrero J. Comorbidity in chronic fatigue syndrome/myalgic encephalomyelitis: A nationwide population-based cohort study. Psychosomatics 2017; 58 533–43.
| Comorbidity in chronic fatigue syndrome/myalgic encephalomyelitis: A nationwide population-based cohort study.Crossref | GoogleScholarGoogle Scholar |
[24] Bhavnani BR, Strickler RC. Menopausal hormone therapy. J Obstet Gynaecol Can 2005; 27 137–62.
| Menopausal hormone therapy.Crossref | GoogleScholarGoogle Scholar |
[25] Schacterle RS, Komaroff AL. A comparison of pregnancies that occur before and after the onset of chronic fatigue syndrome. Arch Intern Med 2004; 164 401–4.
| A comparison of pregnancies that occur before and after the onset of chronic fatigue syndrome.Crossref | GoogleScholarGoogle Scholar |
[26] Raghavan R, Riley AW, Volk H, et al. Maternal multivitamin intake, plasma folate and vitamin b12 levels and autism spectrum disorder risk in offspring. Paediatr Perinat Epidemiol 2018; 32 100–11.
| Maternal multivitamin intake, plasma folate and vitamin b12 levels and autism spectrum disorder risk in offspring.Crossref | GoogleScholarGoogle Scholar |
[27] Jackson ML. Sleep abnormalities in chronic fatigue syndrome/myalgic encephalomyelitis, a review. J Clin Sleep Med 2012; 8 719–28.
| Sleep abnormalities in chronic fatigue syndrome/myalgic encephalomyelitis, a review.Crossref | GoogleScholarGoogle Scholar |
[28] Sieminski M, Szypenbejl J, Partinen E. Orexins, sleep, and blood pressure. Curr Hypertens Rep 2018; 20 79
| Orexins, sleep, and blood pressure.Crossref | GoogleScholarGoogle Scholar |
[29] Carter B, Rees P, Hale L, et al. Association between portable screen-based media device access or use and sleep outcomes. JAMA Pediatr. 2016; 170 1202–8.
| Association between portable screen-based media device access or use and sleep outcomes.Crossref | GoogleScholarGoogle Scholar |
[30] Hoever P, Dorffner G, Benes H, et al. Orexin receptor antagonism, a new sleep-enabling paradigm: a proof-of-concept clinical trial. Clin Pharmacol Ther 2012; 91 975–85.
| Orexin receptor antagonism, a new sleep-enabling paradigm: a proof-of-concept clinical trial.Crossref | GoogleScholarGoogle Scholar |
[31] Bateman L et al. ME/CFS: A Primer for Clinical Practitioners. 2014; 19–20.
[32] Hawk C, Jason LA, Torres-Harding S. Differential diagnosis of chronic fatigue syndrome and major depressive disorder. Int J Behav Med 2006; 13 244–51.
| Differential diagnosis of chronic fatigue syndrome and major depressive disorder.Crossref | GoogleScholarGoogle Scholar |
[33] Chaudhuri A, Behan WMH, Behan PO. Chronic fatigue syndrome. Proc R Coll Physicians Edinb 1998; 28 150–63.
[34] Discussion in ‘BioMedical ME/CFS News’, Apr 19, 2018.
[35] Younger J, Parkitny L, McLain D. The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clin Rheumatol 2014; 33 451–9.
| The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain.Crossref | GoogleScholarGoogle Scholar |
[36] Chang CM, Warren JL, Engels EA. Chronic fatigue syndrome and subsequent risk of cancer among elderly US adults. Cancer 2012; 118 5929–36.
| Chronic fatigue syndrome and subsequent risk of cancer among elderly US adults.Crossref | GoogleScholarGoogle Scholar |
[37] Rajeevan MS, Murray J, Oakley L, et al. Association of chronic fatigue syndrome with premature telomere attrition. J Transl Med 2018; 16 44
| Association of chronic fatigue syndrome with premature telomere attrition.Crossref | GoogleScholarGoogle Scholar |
[38] Rowe KS, Moon J. What is the natural history of chronic fatigue syndrome in young people? Oral presentation IACFS/ME conference Ottawa. Bull IACFS/ME Fall (2011). p. 129.
[39] Cairns R, Hotopf M. Systematic review describing the prognosis of CFS. Occup Med (Lond) 2005; 55 20–31.
| Systematic review describing the prognosis of CFS.Crossref | GoogleScholarGoogle Scholar |